| Literature DB >> 26557361 |
Maria A Villar-Fernandez1, Jose A Lopez-Escamez1.
Abstract
Tympanic membrane perforation is a common problem leading to hearing loss. Despite the autoregenerative activity of the eardrum, chronic perforations require surgery using different materials, from autologous tissue - fascia, cartilage, fat or perichondrium - to paper patch. However, both, surgical procedures (myringoplasty or tympanoplasty) and the materials employed, have a number of limitations. Therefore, the advances in this field are incorporating the principles of tissue engineering, which includes the use of scaffolds, biomolecules and cells. This discipline allows the development of new biocompatible materials that reproduce the structure and mechanical properties of the native tympanic membrane, while it seeks to implement new therapeutic approaches that can be performed in an outpatient setting. Moreover, the creation of an artificial tympanic membrane commercially available would reduce the duration of the surgery and costs. The present review analyzes the current treatment of tympanic perforations and examines the techniques of tissue engineering, either to develop bioartificial constructs, or for tympanic regeneration by using different scaffold materials, bioactive molecules and cells. Finally, it considers the aspects regarding the design of scaffolds, release of biomolecules and use of cells that must be taken into account in the tissue engineering of the eardrum. The possibility of developing new biomaterials, as well as constructs commercially available, makes tissue engineering a discipline with great potential, capable of overcoming the drawbacks of current surgical procedures.Entities:
Keywords: cells; growth factors; myringoplasty; regenerative medicine; scaffold material; tympanic membrane perforation
Year: 2015 PMID: 26557361 PMCID: PMC4627121 DOI: 10.4081/audiores.2015.117
Source DB: PubMed Journal: Audiol Res ISSN: 2039-4330
Figure 1.Schematic structure of the tympanic membrane. The tympanic membrane is trilaminar, consisting of an outer epithelial layer formed by keratinocytes; a fibrous middle layer consisting of fibroblasts and collagen - mainly type II and III - (lamina propria); and an inner mucosal non-keratinized epithelium layer. The thickness of the eardrum is heterogeneous in different locations, ranging from 30 to 150 µm. Most authors adopt a mean value of 74 µm. Modified from Teh et al., 2013.[2]
Comparison between current surgical techniques and tissue engineering for the regeneration of the tympanic membrane.
| Advantages | Disadvantages |
|---|---|
| Myringoplasty/Tympanoplasty | |
| High success rate | Required anesthesia |
| Good outcome in small perforations | Greater surgery time |
| Minimally invasive technique | Open surgical procedure (associated risks) |
| Routine clinical practice | Incision to take the graft and remove squamous epithelium |
| Limited availability of autologous graft in revision cases | |
| Failure of perforation closure due to the deficient regenerative activity at the edges of the injury | |
| Frequent re-perforation | |
| Bilaminar neomembrane: flaccid and acoustically suboptimal | |
| Side effects: retraction pockets, tympanosclerotic mass, rejection | |
| Surgery simplification | Mostly animal studies (acute perforations, which would spontaneously close in most cases) |
| Cost savings | |
| Improve outcome in chronic perforations | Lack of a standard animal model |
| Growth factors improve tympanic closure | Scarce human clinical trials |
| Specific design of scaffold materials that reproduce the mechanical properties of the eardrum | Possible side effects of scaffold materials, biomolecules and cells |
| Ethical and legal issues concerning the use of xenografts | |
| Possibility of generating a commercially available tympanic membrane | Complex manufacture of the artificial construct (storage, biopreservatives, quality controls, production and transportation costs) |
Polymers used for tympanic membrane regeneration by tissue engineering.
| Polymer | Model | Properties and main findings |
|---|---|---|
| Gelfoam®[ | Human | Hemostatic absorbable material used to hold the graft and as a scaffold to growth factors delivery |
| Polylysine polymerized with latex[ | Human | Induction of greater tissue vascularization (possible presence of vascular growth factor, which improves vascularization of the fascia graft by promoting angiogenesis) |
| Silk fibroin[ | Maintenance of keratinocyte growth and cell adhesion and integrity | |
| Animal | Transparent and trilaminar structure of the neomembrane similar to the native membrane | |
| Chitosan[ | ||
| Water-soluble | Animal | Healing rate comparable to natural healing rate |
| Water-insoluble | Animal | Better proliferation of tympanic membrane cells |
| 3D scaffold | Animal | Good cell proliferation |
| Calcium alginate[ | Animal | Growth promotion of mucosal and keratinized epithelium |
| Hyaluronic acid[ | Animal | Reduced time and increased rate of tympanic closure |
| Human | Its application on its own (Epifilm®) does not improve perforation closure rate | |
| Epidisc™ application with a fat graft showed a closure rate similar to fat or cartilage myringoplasty and reduced surgery time | ||
| Poly (glicerol sebacate)[ | Animal | Biodegradability |
| Hydrogels and sponges derived from glycosaminoglycans[ | Animal | Increased re-epithelialization |
| Bilaminar atelocollagen- silicone membrane[ | Human | Biocompatibility |
Carbylan-GSX, Carbylan-S/Gelatin-DTPH; CS-SX, cross-linked thiolated chondroitin sulfate [CS-DTPH-PEGDA (CS-SX)]; bFGF, basic fibroblast growth factor.
Biomolecules used for tympanic membrane regeneration by tissue engineering.
| Biomolecule | Properties | Model | Main findings |
|---|---|---|---|
| EGF[ | Mitogenic effect | Animal | Greater tympanic closure in less time |
| Human | No improvement of tympanic closure | ||
| TGF-α[ | More effective than EGF in promoting colony dispersion and injuries healing | ||
| Animal | TGF-α was not observed in normal TM, but it was expressed after a perforation | ||
| TGF-β[ | Chemotaxis induction | Animal | Reduction of perforation closure time |
| PGF[ | Stimulation of fibroblast, endothelial cells and keratinocytes proliferation and differentiation | Animal | Epithelial and/or connective tissue hiperplasia |
| Human | Increased tympanic closure rate and reduced time of TM closure | ||
| KGF[ | Reactive oxygen species detoxyfication | Animal | Enhanced epithelial migration and proliferation in the first steps |
| PDGF[ | Fibroblast mitogen | Animal | Increased tympanic closure rate |
| Human | No increase in tympanic closure | ||
| VEGF[ | Fibroblast mitogen | Animal | VEGF is more specific and important than bFGF in acute perforation closure |
| Autologous serum from peripheral blood[ | Promotion of wound healing | Human | ASET does not require anesthesia, reduces or completely closes chronic perforations and implies a continuous supply of growth factors by the own patient |
| Human umbilical cord serum[ | Large quantity of growth factors (greater concentration of EGF, NGF and TGF-αβ than in autologous serum from peripheral blood) | Animal | Applied with a 3D collagen scaffold, it enhances significantly chronic perforation closure and hearing capacity from early stages than with paper patches |
| Hyaluronic acid[ | Viscoelastic properties | Animal | Reduced time in tympanic perforation closure |
| Human | No increased tympanic closure success rate | ||
| Human insulin[ | Neovascularization | Animal | Beneficial effect in perforation epithelialization |
| Stimulation of keratyn migration | Human | Increased micro-vascularization from the remnants of tympanic membrane or graft towards the perforation, with the induction of inflammation and epithelialization from the perforation edges | |
| Platelet-rich plasma[ | α granules of platelets contain growth factors | Animal | Reduction of the average time of tympanic closure |
| Plasminogen[ | Degradation of fibrin and extracellular matrix proteins | Animal | Reduced time of tympanic closure |
EGF, epidermic growth factor; TM, tympanic membrane; TGF-α, -β, transformant growth factor type α, -β; FGF, fibroblast growth factor; KGF, keratinocyte growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; ASET, autologous serum eardrop therapy; NGF, nerve growth factor; IGF-1, insulin-like growth factor type I.
Cells used for tympanic membrane regeneration in animals.
| Cells | Model | Main findings |
|---|---|---|
| Autologous fibroblasts[ | Guinea pigs | Accelerated tissue regeneration |
| Mouse embryonic stem cells[ | Gerbil | Greater tympanic closure success rate than in controls |
| Rat | No enhanced tympanic closure with respect to controls - No significant differences in TM thickness or strength with respect to controls - No teratoma formation | |
| Human mesenchymal stem cells[ | MSCs are able to grow and differentiate to fibroblast in the different biomaterials | |
| Rat | Greater tympanic closure success rate than in controls |
TM, tympanic membrane.